Orig3n, a Boston-based biotech research company pioneering the future of health through genetics and regenerative medicine, recently announced the initial close of Series B financing with Haitong International serving as the lead investor.

Haitong International joins an esteemed group of existing investors including Hatteras Venture Partners, Alexandria Venture Investments, Labcorp, Spectrum Health Ventures, 180 degree capital, VECTR Ventures, KTB Ventures, DEFTA Partners, MMIC Investment Holdings and Mountain Group Partners. Orig3n has raised over $50 million in capital to date since it was founded in 2014.

An established, international financial institution headquartered in Hong Kong and among the largest investment banks in China, Haitong International is quickly expanding its global reach to the United States through equity investment in high growth companies.

The Series B financing will support Orig3n's international and domestic expansion as well as continued R&D development, empowering customers to access information about their genes to make educated, proactive choices about their lifestyles. Furthermore, the funding will also allow Orig3n to advance its breakthrough regenerative medicine treatments using the world's largest allogenic bank of cells that is HLA-matched to 90 per cent of the U.S. population.